Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase I clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre in Melbourne, Australia; and the Ashford Cancer Centre in Adelaide, Australia. Sun BioPharma, Inc...
712 Vista Boulevard
Waconia, MN 55387
Founded in 2011
Sun BioPharma, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended of December 31, 2016
Mar 30 17
Sun BioPharma, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended of December 31, 2016. For the quarter, the company reported operating loss of $2,113,000 compared to $1,230,000 a year ago. Loss before income tax benefit was $2,326,000 compared to $1,290,000 a year ago. Net loss was $2,235,000 compared to $595,000 a year ago. Basic and diluted net loss per share was $0.07 compared to $0.02 a year ago.
For the full year, the company reported operating loss of $5,168,000 compared to $5,444,000 a year ago. Loss before income tax benefit was $5,453,000 compared to $5,683,000 a year ago. Net loss was $5,112,000 compared to $4,927,000 a year ago. Basic and diluted net loss per share was $0.16 compared to $0.35 a year ago. Net cash used in operating activities was $2,398,000 compared to $3,897,000 a year ago. The net cash used in each of these periods primarily reflects the net loss for these periods, partially offset in part by non-cash charges recorded for share-based compensation and the effects of changes in operating assets and liabilities.
Sun BioPharma Inc. Announces Interim Data from Phase I Pancreatic Cancer Study
Mar 30 17
Sun BioPharma, Inc. has announced interim data from the Phase I dose-escalation phase of its clinical study for SBP-101 indicated for the treatment of pancreatic cancer. As previously announced on December 7, 2016, the company completed cycle 1 dosing of patients in the fourth cohort and initiated enrollment of the fifth cohort in the dose-escalation phase of the study. The company expects that the additional patients in the fifth cohort will complete cycle 1 dosing early in the second quarter of 2017. Through four completed cohorts, 15 patients have received escalating doses of SBP-101. Seven patients were dosed in the third and fourth cohorts, three of whom have shown stable disease at the eight-week conclusion of their first cycle of treatment, using the independently published Response Evaluation Criteria in Solid Tumors ("RECIST") criteria. These early signs of efficacy were unexpected due to the low doses of SBP-101 administered in these two cohorts and given that six of the seven patients were enrolled in the study after receiving two or more unsuccessful chemotherapy regimens.
Sun BioPharma, Inc. Auditor Raises 'Going Concern' Doubt
Mar 30 17
Sun BioPharma, Inc. filed its 10-K on Mar 30, 2017 for the period ending Dec 31, 2016. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.